Durability of platelet response after switching to avatrombopag from eltrombopag or romiplostim in immune thrombocytopenia

被引：1
|
作者：
Al-Samkari, Hanny [1 ,2 ,9 ]
Jiang, Debbie [3 ,4 ]
Gernsheimer, Terry [3 ,4 ]
Liebman, Howard [5 ]
Lee, Susie [5 ]
Bernheisel, Chelsea
Wojdyla, Matthew [6 ]
Vredenburg, Michael [6 ]
Cuker, Adam [7 ,8 ]
机构：
[1] Massachusetts Gen Hosp, Div Hematol, Boston, MA 02114 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] Univ Washington, Div Hematol, Seattle, WA USA
[4] Seattle Canc Care Alliance, Seattle, WA USA
[5] Univ Southern Calif, Keck Sch Med, Hematol, Los Angeles, CA USA
[6] Sobi Inc, Durham, NC USA
[7] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA USA
[8] Univ Penn, Perelman Sch Med, Dept Pathol & Lab Med, Philadelphia, PA USA
[9] Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA
来源：
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS | 2023年 / 7卷 / 03期
关键词：
avatrombopag; eltrombopag; immune thrombocytopenia; romiplostim; thrombopoietin receptor;
D O I：
10.1016/j.rpth.2023.100134
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Outcomes of switching to avatrombopag following treatment failure with eltrombopag in paediatric immune thrombocytopenia: A real-world study in China
    Cheng, Xiaoling
    Wang, Zhifa
    Dong, Shuyue
    Ma, Jingyao
    Meng, Jinxi
    Wang, Xiaoling
    Wu, Runhui
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, : 636 - 644
  • [22] Efficacy Analyses from the Immune Thrombocytopenia (ITP) Clinical Development Program for Avatrombopag: Comparisons with Placebo and Eltrombopag
    Tarantino, Michael D.
    Vredenburg, Michael
    Tian, Wei
    Jamieson, Brian
    Patel, Kashyap B.
    BLOOD, 2020, 136
  • [23] Role of thrombopoietin stimulating agents (Eltrombopag and Romiplostim) in immune thrombocytopenia secondary to SLE
    Toro-Velez, Esteban
    Nova-Escobar, Santiago
    Jaramillo-Arroyave, Daniel
    IATREIA, 2021, 34 (03) : 253 - 259
  • [24] Thrombopoietin Receptor Agonists Eltrombopag and romiplostim for the treatment of chronic immune thrombocytopenia purpura
    Atkinson, Katie
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2019, 23 (02) : 212 - 216
  • [25] EFFECT OF INDIVIDUALIZED ELTROMBOPAG DOSING ON PLATELET RESPONSE IN PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA
    Stasi, R.
    Meyer, O.
    Vasey, S.
    Brainsky, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 77 - 77
  • [26] Immune thrombocytopenia successfully treated with eltrombopag following multiple therapies including romiplostim
    Sartori, Roberto
    Candiotto, Laura
    Ruggeri, Marco
    Tagariello, Giuseppe
    BLOOD TRANSFUSION, 2014, 12 : S151 - S152
  • [27] Response of Refractory Immune Thrombocytopenia After Bone Marrow Transplantation to Romiplostim
    Beek, Jill C.
    Burke, Michael J.
    Tolar, Jakub
    PEDIATRIC BLOOD & CANCER, 2010, 54 (03) : 490 - 491
  • [28] Romiplostim Dose Response in Patients With Immune Thrombocytopenia
    Perez-Ruixo, J. J.
    Green, B.
    Doshi, S.
    Wang, Y. -M.
    Mould, D. R.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 52 (10): : 1540 - 1551
  • [29] Durability of Initial Platelet Count Response in Patients Treated with Avatrombopag for Immune Thrombocytopenia (ITP): Post-Hoc Results from a Phase 3 Clinical Study
    Jain, Shivi
    Wojdyla, Matthew
    Vredenburg, Michael
    Jamieson, Brian
    Gernsheimer, Terry B.
    BLOOD, 2020, 136
  • [30] Initial romiplostim dosing and time to platelet response in patients with treatment refractory immune thrombocytopenia
    DasGupta, Ryan K.
    Levine, Lauren
    Wiczer, Tracy
    Cataland, Spero
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (03) : 567 - 576
12345